STK38

Serine/threonine-protein kinase 38 · Q15208 · STK38 on Sugi Atlas →

743 patent compounds predicted against STK38, 675 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bay-1161909 (SCHEMBL15036597)	1.00	1/20
Bay-1161909 (SCHEMBL15036679)	1.00	1/20
Bay-1161909 (SCHEMBL19729431)	1.00	1/20
SCHEMBL25250446	1.00	1/20
SCHEMBL25297658	1.00	1/20
SCHEMBL25298174	1.00	1/20
Bay-1161909 (SCHEMBL19716255)	0.89	1/20
Bay-1161909 (SCHEMBL19716256)	0.89	1/20
Bay-1161909 (SCHEMBL19716251)	0.88	1/20
Bay-1161909 (SCHEMBL19716252)	0.88	1/20
SCHEMBL25245097	0.87	1/20
SCHEMBL15415858	0.85	1/20
SCHEMBL15434339	0.85	1/20
SCHEMBL15036890	0.85	1/20
SCHEMBL25297787	0.84	1/20
SCHEMBL25298434	0.84	1/20
SCHEMBL25298740	0.84	1/20
SCHEMBL25793298	0.84	1/20
SCHEMBL25247162	0.83	1/20
SCHEMBL25293297	0.83	1/20

Clinical trials — most relevant to STK38 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	PHASE2	COMPLETED
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors	PHASE1/PHASE2	NOT_YET_RECRUITING
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)	PHASE2	COMPLETED
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations	PHASE2	COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer	PHASE2	RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients	PHASE2	COMPLETED
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Study of XL418 in Adults With Solid Tumors	PHASE1	SUSPENDED
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.	PHASE1	ACTIVE_NOT_RECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Exercise in Type 1 Diabetes Mellitus	nan	COMPLETED
Biomarker Analysis of Gastrointestinal Cancer	nan	UNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a STK38 binder may also engage these)

Protein	Name	Similarity
Q5R8M1	—	1.000	Q5R8M1 →
Q91VJ4	—	1.000	Q91VJ4 →
A2VDV2	—	1.000	A2VDV2 →
STK38L	Serine/threonine-protein kinase 38-like	1.000	landscape →
Q7TSE6	—	1.000	Q7TSE6 →
Q9NBK5	—	1.000	Q9NBK5 →
Q2LZZ7	—	1.000	Q2LZZ7 →
Q2L6W9	—	0.998	Q2L6W9 →
A8XJL7	—	0.998	A8XJL7 →
O13310	—	0.998	O13310 →
STK32A	Serine/threonine-protein kinase 32A	0.995	landscape →
RPS6KB1	Ribosomal protein S6 kinase beta-1	0.995	landscape →
Q6TJY3	—	0.995	Q6TJY3 →
Q8BSK8	—	0.994	Q8BSK8 →
Q12706	—	0.994	Q12706 →
Q9JJX8	—	0.994	Q9JJX8 →
Q8BGW6	—	0.993	Q8BGW6 →
Q6PFQ0	—	0.992	Q6PFQ0 →
P09215	—	0.992	P09215 →
Q6TGC6	—	0.991	Q6TGC6 →
Q39030	—	0.991	Q39030 →
Q62074	—	0.991	Q62074 →
PRKCD	Protein kinase C delta type	0.990	landscape →
Q5R4K3	—	0.990	Q5R4K3 →
Q64682	—	0.990	Q64682 →
Q09639	—	0.990	Q09639 →
A8XJQ6	—	0.990	A8XJQ6 →
Q5RD00	—	0.990	Q5RD00 →
P18654	—	0.990	P18654 →
Q8C050	—	0.990	Q8C050 →